MB

MRCF Biomedical Translation Fund

Description

The MRCF Biomedical Translation Fund provides support for the commercialization of health and medical research outcomes.

Investor Profile

MRCF Biomedical Translation Fund has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A rounds (top funding stages).
  • Majority of deals are located in Australia.
  • Strong thematic focus on Biotechnology, Health Diagnostics, Medical.

Stage Focus

  • Series A (100%)

Country Focus

  • Australia (100%)

Industry Focus

  • Biotechnology
  • Health Diagnostics
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does MRCF Biomedical Translation Fund frequently co-invest with?

HESTA
Oceania, Victoria, Australia, Melbourne
Co-Investments: 1
Uniseed
Oceania, Queensland, Australia, Brisbane
Co-Investments: 1
AustralianSuper
Oceania, Victoria, Australia, Melbourne
Co-Investments: 1
Statewide Super
Oceania, South Australia, Australia, Adelaide
Co-Investments: 1
UC
North America, Michigan, United States, Northville
Co-Investments: 1
CSL
Oceania, Victoria, Australia, Melbourne
Co-Investments: 1
Hostplus
Oceania, Victoria, Australia, Melbourne
Co-Investments: 1
Brandon Capital
Oceania, Victoria, Australia, Melbourne
Co-Investments: 1
Stoic VC
Oceania, New South Wales, Australia, Sydney
Co-Investments: 1

What are some of recent deals done by MRCF Biomedical Translation Fund?

Ena Respiratory

Melbourne, Victoria, Australia

Ena Respiratory researches and develops solutions to transform the treatment and prevention of respiratory infections.

BiotechnologyHealth DiagnosticsMedical
Series ASep 28, 2020
Amount Raised: $8,299,573